Plasma tetranectin and ovarian neoplasms.
Plasma tetranectin was measured in 67 controls, 121 patients with a benign or malignant ovarian tumor, and 24 patients with another benign gynecologic disease to evaluate the predictive value of plasma tetranectin. A significant reduction of plasma tetranectin was found in every malignant tumor type except for mucinous tumors. Further a significant correlation was found between stage of tumors and plasma tetranectin. Depending on the cutoff level the sensitivity for stage 1 cancer ranged from 52 to 71%. In stage 1 + 2 the sensitivity ranged from 58 to 75% and for advanced cancer (stage 3 + 4) from 80 to 95%. The corresponding specificities ranged from 97 to 84%. Plasma tetranectin may be a useful tool for detecting early stages of ovarian cancer.
Høgdall
C K
CK
Department of Obstetrics & Gynecology, Rigshospitalet, University of Copenhagen, Denmark.
Høgdall
E V
EV
Hørding
U
U
Daugaard
S
S
Clemmensen
I
I
Nørgaard-Pedersen
B
B
Toftager-Larsen
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001798:Blood Proteins / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D037181:Lectins, C-Type; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology; D012016:Reference Values; D012680:Sensitivity and Specificity
D001798:Blood Proteins; D037181:Lectins, C-Type; C048648:tetranectin